leadf
logo-loader
viewMotif Bio PLC

Motif Bio PLC gets ball rolling for iclaprim NDA

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive's Andrew Scott they've initiated a rolling submission of a new drug application to the US Food & Drug Administration for iclaprim.

The new drug application (NDA) for their flagship next-generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is expected to be completed during the second quarter of 2018.

Quick facts: Motif Bio PLC

Price: 0.5 GBX

AIM:MTFB
Market: AIM
Market Cap: £3.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Kavango Metals 'gearing up' after announcing Botswana joint venture with...

Kavango Resources PLC's (LON:KAV) Mike Moles speaks to Proactive London following the announcement of the Botswana strategic joint venture with Power Metal Resources. The venture will see the formation of a new, jointly owned, privately held company that is focussed on large-scale mineral...

12 hours, 23 minutes ago

2 min read